Feb 26 (Reuters) - EU Medicines Agency
* Recommends Approval Of CSL Ltd's CSL.AX albutrepenonacog alfa to treat Haemophilia b
* Scientific review of known risk of PML with the multiple sclerosis medicine Tysabri is now completed, with CHMP confirming PRAC recommendations
* Gilead's Descovy (emtricitabine / tenofovir alafenamide) received a positive opinion for the treatment of HIV infection
* Confirmed recommendations from PRAC to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors, a class of type 2 diabetes medicines Source text Further company coverage: CSL.AX